1.The Knowledge, Attitudes and Practices of Primary Pediatric Caregivers towards COVID-19 in a Tertiary Hospital
Joan Paola N. Castañ ; eda ; John Robert C. Medina ; Carlo R. Lumangaya ; Maria Margarita M. Lota
Philippine Journal of Health Research and Development 2021;25(COVID-19 Supplement):1-7
Background:
Coronavirus disease 2019 (COVID-19) is a respiratory disease that causes remarkable morbidities and mortalities worldwide. Public health measures have been implemented to control the spread of the disease. Knowledge, attitudes, and practices (KAP) of the community have to be optimum for the successful implementation of the prevention and control measures.
Objective:
Cognizant that children may possibly contribute to community transmission and that primary
caregivers are the main educators of their children and implementers of preventive measures at the household level, the study aimed to determine the KAP of primary caregivers towards COVID-19 in a private tertiary hospital in Metro Manila, Philippines.
Methodology:
The study utilized a descriptive, cross-sectional design employing a web-based self-administered survey to determine the KAP of primary caregivers towards COVID-19 in a tertiary hospital.
Results:
There were a total of 149 respondents. Participants had a generally high knowledge of COVID-19, its symptomatology, and its prevention. Most of the respondents agreed that vaccination, quarantine, and community quarantine are necessary to prevent transmission. Primary caregivers responded that they protected their children by avoiding exposure and observing good hygiene measures. Despite the ongoing pandemic, most respondents would still bring their children to the doctor for routine vaccinations and consultations at the hospital when sick.
Conclusion
The findings of the study revealed a generally good KAP among the primary caregivers of pediatric patients which can help ensure the prevention and control of COVID-19. A strong health education campaign is needed to provide accurate information that will help sustain and/or increase compliance with COVID-19 prevention and control measures.
COVID-19
;
Knowledge
;
Attitude
2.A narrative review of pneumococcal conjugate vaccine choices for greater access and protection against pneumococcal diseases in the Philippines.
Maria Margarita M. LOTA ; Ma. Rosario Z. CAPEDING ; Fernando B. GARCIA JR. ; John Robert C. MEDINA ; Jeremiah A. SERRANO ; Carlo R. LUMANGAYA ; Vicente Y. BELIZARIO JR.
Acta Medica Philippina 2025;59(4):151-158
BACKGROUND
Pneumococcal vaccination has been widely used for the prevention of pneumococcal disease, with two types of vaccines available since 2009. With the World Health Organization (WHO) recommendation of incorporating pneumococcal conjugate vaccines (PCVs) in National Immunization Programs (NIPs) worldwide, a ten-valent PCV (PHiD-CV) was initially introduced in the Philippines in 2012. This, however, transitioned to the use of the 13-valent PCV (Prevnar) subsequent to the recommendation of the Formulary Executive Council in 2014.
OBJECTIVEThis review aimed to present evidence on pneumococcal disease and vaccine inclusion in the Philippine NIP from 2005 - 2021.
METHODSThis narrative review compiled articles on Pneumococcus from January 2005 to October 2021, sourcing literature from databases such as BIOSIS Preview, CAB Direct, Embase, Google Scholar, and others.
RESULTSIn the Philippines, there was a shift in prevalent serotypes of Streptococcus pneumoniae among children under five following the introduction of PCV13 in the National Immunization Program in 2014, with serotype 14 becoming the most common by 2018, and a significant reduction in isolates reported in 2020, where only serotypes 5, 19A, and 23F were identified among invasive strains. The immunogenicity results of a potential vaccine candidate should be factored into the overall evidence when conducting a reassessment of PCV.
CONCLUSIONAs part of the decision making about the inclusion of the PCVs in the NIP of the Philippines, various factors such as local epidemiology, vaccine supply, cost, and programmatic characteristics must be careful weighed. Enhancing laboratory and surveillance capacity are essential to provide evidencebased decision-making in terms of existing serotype distribution and antimicrobial resistance (AMR) profile in the country. With the introduction of a new affordable formulation of a 10-valent PCV offering a comparable serotype coverage, the reassessment of choice of PCV with the consideration of all three formulations, namely PCV13, PHiD-CV, and SIIPL-PCV, may be warranted.
Bacteria ; 10-valent Pneumococcal Conjugate Vaccine ; 13-valent Pneumococcal Vaccine ; Pneumococcal Vaccines ; Philippines
3.A review of workplace tuberculosis policies in selected low- and middle-income countries in Asia-Pacific.
Evalyn A. ROXAS ; Vivien Fe F. FADRILAN-CAMACHO ; Paul Michael R. HERNANDEZ ; Maria Margarita M. LOTA ; Loisse Mikaela M. LOTERIO ; Adrian Paul M. AGRAVANTE ; Daniella Kate B. CORPUZ ; Carlo R. LUMANGAYA ; Richelle Liza F. MAGLALANG ; Micaela J. AREVALO ; Vicente Y. BELIZARIO JR.
Acta Medica Philippina 2025;59(4):65-77
BACKGROUND AND OBJECTIVE
The World Health Organization (WHO) reported that most of the tuberculosis (TB) cases are aged between 15 to 54 years old, the working population. This study described workplace policies on TB in selected low- and middle-income countries (LMIC) in Asia-Pacific.
METHODSAmong the LMICs, countries wherein TB is a public health concern were included. Six policies written in English were included in this study and were reviewed based on the components of the TB workplace programs that were extracted from the WHO Guidelines for Workplace TB Control Activities.
RESULTSThe Philippine policy had the most number of components while those of Cambodia and Papua New Guinea had the least. Only the component on implementing environmental controls was common among the policies. Components on respecting patient rights and confidentiality, tailoring of workload to TB patient’s state of health, registration of all patients with TB diagnosis, reporting of cases to central NTP office, recording of standard treatment outcome, and inclusion of multidrug-resistant TB (MDR-TB) provisions were missing for the majority of the policy documents.
CONCLUSIONThe workplace TB program policies included in this study can be reviewed and updated accordingly, with the coverage expanding to all workplaces. The policies can also integrate measures on COVID-19 as the pandemic has slowed the progress in TB control. With the similarities in the preventive measures against TB and COVID-19, this can be an avenue to develop integrated policies especially for workplaces.
Human ; Tuberculosis